Placeholder Banner

BIO Premieres New Ad Highlighting the Value of Biomedical Innovation

February 8, 2016

Washington, D.C. (February 8, 2016) – The Biotechnology Innovation Organization (BIO) today launched a new ad focused on the value of biomedical innovation, highlighting the most compelling benefits of biomedical research – giving patients time to live fuller lives. The ad serves as a cornerstone for BIO’s new Value Campaign, which will provide an avenue for the biotechnology sector to highlight the value of biomedical innovation and includes a new “Time Is Precious” website.

“With this effort, BIO is advancing the national public policy debate over the cost and value of medicine, shining a spotlight on the fact that innovative, life-saving medicines provide benefits far beyond their costs,” said BIO President & CEO Jim Greenwood. “It’s time for the public to hear the voices of those who are benefitting from medical breakthroughs and those who are bringing these breakthroughs to market.”

Through the campaign, the public will see that today’s innovative life-enhancing medicines save and extend lives, improve quality of life and drive value to patients and the healthcare system as a whole. The ad represents just the beginning of BIO’s campaign, which includes a new “Time Is Precious” website.

“Thanks to biomedical breakthroughs we have seen HIV/AIDS death rates drop by 85% since 1995; heart disease death rates have decreased by 30% between 2001 and 2011, and cancer death rates are down 22% since 1991. America’s innovative biopharmaceutical companies are tackling some of our most unrelenting scientific challenges head-on and are delivering new, high-value cures and treatments that are saving and extending the lives of patients and giving them precious time to lead fuller lives,” said Greenwood.

The Value of Medicine advertisement can be viewed HERE.For more information on the advertisement or BIO’s Value Campaign, please visit: http://timeisprecious.life

###

Discover More
Today the dispute settlement panel formed under the United States-Mexico-Canada Agreement (USMCA) issued a final ruling related to Mexico's restrictions on the importation of genetically modified (GM) corn. In response, John Crowley, President…
John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), today released the following statement ahead of an expected vote in the U.S. House of Representatives on a year-end government funding bill that includes many…
Today, the Biotechnology Innovation Organization (BIO) named Sarah Alspach as its new executive vice president and chief communications officer. Alspach, a communications veteran, will join BIO’s senior leadership team. Her first day will be…